In Europe and North America, estrogen/progestogen oral contraception has been
associated with an increase in venous thromboembolism, myocardial infarction, and stroke …

Oral contraceptives influence plasma proteins, causing changes in plasma procoagulants
and fibrinolytic effectors. Estrogen is thought to be responsible for these changes, whereas …

Clinical and epidemiological data indicate that the oral contraceptives are thrombogenic.
The important papers concerning the effects of oral contraceptives on hemostatic …

Oral contraceptives have been linked to an increased incidence of thrombovascular
disease. This may be mediated by their effects on the haemostatic system. An increase in …

Three large British studies on the vascular effects of oral contraceptives have established
that the risk of thrornboembolic episodes, both venous and arterial, rises with increasing …

An increased risk of venous thrombosis has been demonstrated in women receiving oral
contraceptives (OCs). This risk has been primarily associated with the oestrogen content, but …

PIP: Studies on the adverse effects of oral contraceptives (OCs) on blood clotting in which
selected groups of women taking OCs were monitored for coagulation and platelet changes …

Objective To determine the effect of oestrogen dose and progestogen type on the
coagulation and fibrinolytic systems of a group of normal healthy women taking three …

Oral contraceptives (OCs) raise the plasma levels of some clotting factors, especially factor
VII. Until recently, however, there has been no evidence for a relationship between high …

Since the introduction of oral contraceptives, their use has been associated with an
increased risk of both venous and arterial thrombosis. Pulmonary embolism, myocardial …